24-Apr-2026
BeOne Medicines to Announce First Quarter 2026 Financial Results on May 6
Business Wire (Wed, 22-Apr 6:01 AM ET)
ONC Delivers Robust Revenue Growth and Pipeline Progress Amid Record Free Cash Flow
Market Chameleon (Thu, 26-Feb 3:40 AM ET)
Business Wire (Thu, 26-Feb 6:00 AM ET)
BeOne Medicines to Present at Upcoming Investor Conferences
Business Wire (Tue, 17-Feb 6:00 AM ET)
BeOne Medicines to Announce Fourth Quarter and Full Year 2025 Financial Results on February 26
Business Wire (Wed, 11-Feb 6:00 AM ET)
ZIIHERA-Based Regimens Set to Redefine First-Line HER2-Positive Gastric Cancer Treatment
Market Chameleon (Mon, 17-Nov 4:02 AM ET)
Market Chameleon (Thu, 6-Nov 3:47 AM ET)
BeOne Medicines Ltd is a holding company. Through its subsidiaries, it operates as an oncology-focused biopharmaceutical company engaged in the discovery and development of treatments for cancer. Its portfolio includes BRUKINSA (a Bruton's tyrosine kinase (BTK) inhibitor), sonrotoclax (a B-cell lymphoma 2 (BCL2) inhibitor, and a BTK chimeric degradation activation compound (BTK-CDAC). The company develops and commercializes wholly owned therapeutic assets targeting multiple mechanisms of action in oncology. The company operates in one segment: pharmaceutical products. It generates the majority of its revenue from the sale of its biopharmaceutical products.
Beone Medicines Ltd. - American Depositary Shares trades on the NASDAQ stock market under the symbol ONC.
As of April 24, 2026, ONC stock price climbed to $300.80 with 148,529 million shares trading.
ONC has a beta of 0.63, meaning it tends to be less sensitive to market movements. ONC has a correlation of 0.04 to the broad based SPY ETF.
ONC has a market cap of $33.39 billion. This is considered a Large Cap stock.
Last quarter Beone Medicines Ltd. - American Depositary Shares reported $1 billion in Revenue and $1.95 earnings per share. This beat revenue expectation by $45 million and exceeded earnings estimates by $.53.
The top ETF exchange traded funds that ONC belongs to (by Net Assets): IBB, FBT, CGGE, BBH, CGIE.
ONC has underperformed the market in the last year with a price return of +17.4% while the SPY ETF gained +31.9%. ONC has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -11.4% and -2.9%, respectively, while the SPY returned +3.8% and +5.1%, respectively.
ONC support price is $292.75 and resistance is $306.87 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ONC shares will trade within this expected range on the day.